FDA approved Cyramza (ramucirumab), sponsored by Eli Lilly, as a single agent for hepatocellular carcinoma in patients who have an alpha fetoprotein of ≥ 400 ng/mL and have been previously treated with sorafenib.
An analysis by researchers from the International Agency for Research on Cancer casts doubt on validity of an endpoint used in key studies of multi-cancer detection tests.
